Citation: Tovar N, Fernández de Larrea C, Aróstegui JI, Cibeira MT, Rosiñol L, Rovira M, Elena M, Filella X, Yagüe J, and Bladé J. Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem-cell transplantation: long-term results from a single institution. Haematologica. 2013; 98:xxx doi:10.3324/haematol.2013 Haematologica (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435, www.haematologica.org) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by the Ferrata Storti Foundation, a non-profit organization, and serves the scientific community with strict adherence to the principles of open access publishing (www.doaj.org). In addition, the journal makes every paper published immediately available in PubMed Central (PMC), the US National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature. 
INTRODUCTION
Multiple myeloma (MM) is characterized by the production of a monoclonal immunoglobulin of constant isotype and light chain restriction due to the clonal proliferation of neoplastic plasma cells 1 . Complete remission (CR) definition in MM requires the absence of the original monoclonal protein in both serum and urine immunofixation (IFE) [2] [3] [4] . The relapse from CR always occurs with the same monoclonal component observed at diagnosis 5 . However, the emergence of an oligoclonal humoral response, resulting in the appearance of a serum M-protein different from that at diagnosis is a well-recognized event after autologous stem cell transplantation in multiple myeloma (MM), and it has been considered as a benign phenomenon [5] [6] [7] . Though initially described as transient 6 , there is growing evidence that this oligoclonal humoral response can last for years 5, 7, 8 . In addition, the appearance of oligoclonal bands has also been reported with higher frequency after treatment with novel drugs 9 , such as lenalidomide, thalidomide and bortezomib, than with conventional cytotoxic therapy 10 .
The optimal treatment in patients with MM younger than 65 years includes induction therapy followed by high-dose therapy with autologous peripheral blood stem-cell rescue (ASCT) 11 . Patients who developed a humoral response resulting in oligoclonal bands seem to have a better prognosis in terms of progression-free survival and overall survival 6, 8, 9, 12 . However, the reports on this issue are controversial 7, 13, 14 . The aim of the present study was to investigate the incidence, biological characteristics and prognostic value of the oligoclonal bands in patients with MM who underwent ASCT at our institution in the last 18 years.
METHODS

Patients
Two hundred and eleven patients underwent melphalan-based ASCT at our institution dexamethasone (7%) or other combinations (9.1%). In the second group, the induction regimen was based on combinations of glucocorticoids with bortezomib (59%; including 8 patients with VBCMP/VBAD), thalidomide (30%), or with bortezomib plus thalidomide (11%).
Eighty-seven out of the 199 patients (43.7%) achieved CR after ASCT. The median progression-free survival (PFS) and overall survival (OS) after ASCT were 3.2 and 6.6 years, respectively. Oligoclonal bands after ASCT were observed in 34% (67/199) of the patients. The characteristics of the patients with or without this humoral response are summarized in Table 2 . The median number of different isotypes accounting for oligoclonal humoral response was 2 (range 1 to 6). Humoral oligoclonal response lasted for a median of 1.35 years (range 3 months to 11+ years). Oligoclonal bands were more frequently observed in serum than in urine (75.4% vs. 31.6%) and the most usually involved serum heavy-chain was IgG (73%), with almost the same kappa/lambda distribution. Kappa light-chain was the predominant isotype in the urine (60%).
In the overall series, the dissapereance of the oligoclonal bands preceeded serological relapse in all cases, except in two settings. Patients with oligoclonal humoral response lasting for more than one year after ASCT had a significantly longer clinical PFS and OS than those with shorter duration (p=0.008 and p=0.0001, respectively). Of note, the estimated OS of patients with oligoclonal bands lasting for more than one year was 70% at 10 years. In contrast, the PFS ad OS of patients with oligoclonal bands lasting for less than one year were similar to those who never developed this phenomena. In patients in CR after ASCT, the presence or absence of oligoclonal humoral response was not associated with a significant PFS or OS prolongation, even when the duration of CR and oligoclonal responses were studied as time-dependant covariates.
The results of the univariate and multivariate analysis are summarized in Table 3 . For PFS, a model including oligoclonal response, ISS and heavy chain isotype (IgG vs. nonIgG patients) was able to predict longer PFS. Concerning OS, only the ISS and oligoclonal response remained at significant level.
DISCUSSION
The existence of an oligoclonal humoral response, detectable in serum and more rarely in urine, is a well-recognized phenomenon 15 . It can be found during the development of the B-cell response during the childhood, and in different clinical settings 16 . Even a localized production in the cerebrospinal fluid is a common finding in multiple sclerosis 17 . There is evidence of this type of response in the serum of patients with systemic infections, autoimmune disorders, immunosupression in the context of organ transplantation, and also after allogeneic and autologous stem-cell transplantation [18] [19] . It seems that, in the context of ASCT for MM, the emergence of these oligoclonal immunoglobulins can be a consequence of a strong immune reconstitution.
Since this phenomena was first recognized 6 , a number of studies on the issue has been reported. The EBMT group emphasized the fact that the presence of monoclonal immunoglobulins in the absence of the original myeloma protein was consistent with CR 3 and that the characterization of serum and urine immunoglobulins with the recognition of oligoclonal bands is crucial in the response evaluation in MM. Although known for more than two decades, most studies on this issue have not been performed until recent years.
A fact that can create some confusion is that the same phenomenon has been described under different terms: oligoclonal or abnormal protein bands (APB) 5, 6 , apparent isotype class switching 6 , atypical serum immunofixation patterns (ASIPs) 9 , or even more as recently, secondary monoclonal gammopathies of undetermined significance (MGUS) 12, 13 .
The incidence of the oligoclonal humoral response is also very wide among different series, ranging from 7 to 73% [5] [6] [7] [8] [9] 12, 13 . In the present study it was 34%. One reason for this discrepancy is the denominator of this percentage. In this regard, it is a phenomenon more frequently observed in patients after ASCT than conventional chemotherapy 10, 12 and this could explain the low percentage reported in the Mayo Clinic series (7%) where almost two thirds of the patients had not received ASCT 12 , or the higher rate of 42% in our previous report with only patients after ASCT or allogeneic SCT in CR were included 7 . Other factor to take into consideration is the use of novel drugs (thalidomide, lenalidomide and bortezomib). Thus, we previously reported a significantly difference when these agents versus conventional chemotherapy were used (60% vs. 11%) in patients in CR after induction not candidates to ASCT 10 . This fact is confirmed in the present series including only patients eligible for ASCT; patients who received any of these drugs during induction show a significantly higher rate (63% vs. 22%) of oligoclonal humoral response. With the continuous improvement in the CR rate and the worldwide use of new drugs in the treatment of patients with MM 20 , the prevalence of oligoclonal bands will likely increase.
Alternance pattern of different oligoclonal was very frequent in our patients. Otherwise, it has been noted that oligoclonal bands can occur in patients not in CR. In contrast to the Mayo report 12 where 82% of the patients with oligoclonal bands were not in CR, we only Concerning the prognostic significance, our results showed that patients with oligoclonal bands after ASCT had a median PFS 2 years longer than those without this humoral response. Furthermore, in our patients this difference was translated into a significantly longer OS. Contradictory results on prognosis have been reported in previous studies 6, 7, 9, 12, 14 . Differences in sample size, induction treatment, populations' heterogeneity and particularly duration of follow up could responsible for the discordant results. In any event,
the presence of oligoclonal bands should be considered as a characteristic of patients in CR rather than an independent prognostic marker.
The duration of oligoclonal bands is also a controversial issue. Thus, from the original Arkansas series and the Mayo Clinic experience, it seems to be limited to several months 12 . In our experience they lasted for a median of 1 to 2 years, persisting during follow-up in all patients except in those who relapsed. The fact of all our patients underwent ASCT could explain the longer oligoclonal response duration due to a deeper malignant clone suppression and/or stronger immunological reconstitution. We also found that a duration of the oligoclonal response longer than one year was associated with a significantly longer OS. Some aspects to be explored but that were out of the scope of our oligoclonal response has not been explored in our study but in the Mayo no association was found 12 . Antigen specificity of oligoclonal bands with potential anti -tumor activity 25 or associated oligoclonal cellular immune response 26 are other new potential research targets.
In summary, the emergence of oligoclonal bands after ASCT is usually observed in patients in CR and it has prognostic impact. This phenomena likely reflect a robust humoral immune response and consequently an immune system reconstitution. Duration of this humoral response is also associated with a significant survival prolongation.
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